- Home
- LPG vs VRDN Comparison
LPG vs VRDN Comparison
Compare LPG & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- VRDN
- Stock Information
- Founded
- LPG 2013
- VRDN 2006
- Country
- LPG United States
- VRDN United States
- Employees
- LPG N/A
- VRDN N/A
- Industry
- LPG Marine Transportation
- VRDN Medical Specialities
- Sector
- LPG Consumer Discretionary
- VRDN Health Care
- Exchange
- LPG Nasdaq
- VRDN Nasdaq
- Market Cap
- LPG 1.4B
- VRDN 1.6B
- IPO Year
- LPG 2014
- VRDN N/A
- Fundamental
- Price
- LPG $26.89
- VRDN $24.12
- Analyst Decision
- LPG Strong Buy
- VRDN Strong Buy
- Analyst Count
- LPG 1
- VRDN 10
- Target Price
- LPG $35.00
- VRDN $36.33
- AVG Volume (30 Days)
- LPG 448.3K
- VRDN 805.8K
- Earning Date
- LPG 10-31-2025
- VRDN 11-11-2025
- Dividend Yield
- LPG 11.90%
- VRDN N/A
- EPS Growth
- LPG N/A
- VRDN N/A
- EPS
- LPG 1.15
- VRDN N/A
- Revenue
- LPG $320,692,009.00
- VRDN $305,000.00
- Revenue This Year
- LPG $17.26
- VRDN N/A
- Revenue Next Year
- LPG N/A
- VRDN $34,044.63
- P/E Ratio
- LPG $23.36
- VRDN N/A
- Revenue Growth
- LPG N/A
- VRDN 5.90
- 52 Week Low
- LPG $16.66
- VRDN $9.90
- 52 Week High
- LPG $33.67
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- LPG 33.02
- VRDN 71.53
- Support Level
- LPG $25.50
- VRDN $20.71
- Resistance Level
- LPG $27.24
- VRDN $22.37
- Average True Range (ATR)
- LPG 0.70
- VRDN 1.02
- MACD
- LPG -0.21
- VRDN 0.19
- Stochastic Oscillator
- LPG 30.54
- VRDN 92.11
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).